About the PBTCF
In the beginning, a Parent/Family committee was formed to lend its support to the PBTC – reviewing concepts and consent forms for the PBTC to ensure information was written in understandable language. In 2007, the PBTC Foundation (formerly Brain Waves) was formed by the Parent/Family Committee as a 501 (3c) nonprofit.
What We Fund
Granted funds to purchase a computer network so that PBTC information and crucial research data is available to all consortium institutions. Hardware form this 2010 grant, Protecting the Research of the Pediatric Brain Tumor Consortium, is housed at St. Jude and is crucial to the success of PBTC fast-track studies.
In 2011, the PBTCF sponsored a first-of-its-kind meeting of national experts in pediatric neuro-imaging. Insights from this meeting drive the design of future studies focused on greater accuracy for detailed diagnoses to pre-empt surgical exploration and to tailor best possible therapies.
The PBTCF underwrites a portion of the costs incurred by every child enrolled in a PBTC clinical research trial. Our ability to sponsor patients is directly related to our fluctuating annual budget.
Annual awards are presented to Clinical Research Associates (CRAs) who exceed the already rigorous standards of excellence at PBTC institutions.
Supported a scientific symposium for basic and translational scientists from PBTC member institutions held prior to the International Symposium of Pediatric Neuro-Oncology (ISPNO).

Clinical Trials
suspended
A Trial of Dabrafenib, Trametinib and Hydroxychloroquine for Patients With Recurrent LGG or HGG With a BRAF Aberration
recruiting
Feasibility Trial of Optune for Children With Recurrent or Progressive Supratentorial High-Grade Glioma and Ependymoma
recruiting
Pembrolizumab in Treating Younger Patients With Recurrent, Progressive, or Refractory High-Grade Gliomas, Diffuse Intrinsic Pontine Gliomas, Hypermutated Brain Tumors, Ependymoma or Medulloblastoma
recruiting
Phase I Study of APX005M in Pediatric CNS Tumors
recruiting
Testing the Safety and Tolerability of CX-4945 in Patients With Recurrent Medulloblastoma Who May or May Not Have Surgery
recruiting
Trial of Panobinostat in Children With Diffuse Intrinsic Pontine Glioma
recruiting
131I-Omburtamab, in Recurrent Medulloblastoma and Ependymoma
not yet recruiting
INCB7839 in Treating Children With Recurrent/Progressive High-Grade Gliomas
active, not recruiting
Pomalidomide in Treating Younger Patients With Recurrent, Progressive, or Refractory Central Nervous System Tumors
active, not recruiting
Selumetinib in Treating Young Patients With Recurrent or Refractory Low Grade Glioma
active, not recruiting
Vorinostat Combined With Isotretinoin and Chemotherapy in Treating Younger Patients With Embryonal Tumors of the Central Nervous System
active, not recruiting
Sign-Up for Updates
Contact Us
Pediatric Brain Tumor Consortium Foundation
10280 Chester Road
Cincinnati, Ohio 45215